Skip to content Skip to footer
Subscribe Now
Viz.ai, Sanofi & Regeneron
News

Viz.ai Enters a Multi-Year Partnership with Sanofi and Regeneron to Improve Management and Care of COPD

Shots: Viz.ai has entered into a multi-year collaboration with Sanofi & Regeneron to deploy and evaluate its AI-powered chronic obstructive pulmonary disease (COPD) workflow solution Sanofi, Regeneron, and Viz.ai collaborated on an AI-powered solution to improve care for high-risk COPD pts, focusing on how the Viz COPD module can enhance EHR workflows, access to care,…
May 21, 2025

Read more

Vant AI & Blueprint Medicines
News

VantAI and Blueprint Medicines Expands License Agreement to Advance Induced Proximity Drug Discovery

Shots: VantAI and Blueprint Medicines have expanded their 2022 collaboration, adding new drug target programs to develop therapies for critical medical needs As per the expansion, VantAI will receive up to $1.67B in total including ~$270M R&D and regulatory milestones, and $1.4B commercial milestones across four joint target programs, along with tiered mid-single-digit sales based…
May 21, 2025

Read more

Brightseed and Haleon
News

Brightseed and Haleon Collaborate to Discover Small Molecule for Human Health Innovation by Leveraging AI Platform Forager

Shots: Haleon and Brightseed have partnered to accelerate the discovery of plant-based bioactive compounds using Brightseed’s AI platform, Forager, supporting Haleon to create innovative health solutions Forager will be directly accessible to Haleon scientists, enabling AI-powered identification of natural compounds and their health-related mechanisms, streamlining R&D and product development Forager bioactive discovery has already demonstrated…
May 2, 2025

Read more

Prilenia & Ferrer
News

Prilenia Therapeutics Collaborates with Ferrer to Co-Develop and Commercialize Pridopidine for Indications Beyond Huntington’s Disease (HD)

Shots: Prilenia & Ferrer have entered into a collaboration & license agreement to co-develop & commercialize pridopidine for indications beyond HD in Europe & select markets, with Prilenia retaining rights in major markets incl. North America, Japan, & APAC As per the deal, Prilenia will receive ~$90.8M upfront, ~$51.1M in near-term development, regulatory, & commercial…
April 28, 2025

Read more

BigHat Biosciences & Eli Lilly
News

BigHat Biosciences Collaborates with Eli Lilly to Advance AI-Driven Antibody Therapeutics

Shots: BigHat Biosciences and Eli Lilly entered into a strategic collaboration to design and develop next-generation therapeutic antibodies using BigHat’s ML-powered Milliner platform and synthetic biology wet lab The collaboration includes up to two antibody programs and support for BigHat’s internal pipeline, including a next-gen ADC for GI cancers entering the clinic in 2026, with…
April 18, 2025

Read more

Alumis & Kaken
News

Alumis and Kaken Pharmaceutical Enter Collaboration & Licencing Deal for ESK-001’s Development & Commercialization in Japan

Shots: Alumis & Kaken have partnered to develop, manufacture, & market ESK-001 for dermatology in Japan, with an option to expand into rheumatology & GI diseases As per the deal, Kaken will handle development, approval & marketing of ESK-001 in Japan in exchange for $40M upfront & near-term co-development costs, with ~$140M in milestones & field…
March 25, 2025

Read more

J&J & Nosis Bio
News

Nosis Biosciences Partners with Janssen Biotech for Cell-Targeted RNA Drugs

Shots: Nosis Biosciences has entered into a strategic collaboration with Janssen Biotech (subsidiary of J&J) to design & develop cell-targeted RNA medicines The collaboration leverages J&J’s drug discovery & clinical expertise as well as Nosis’ Connexa platform to design drugs with extra-hepatic access to multiple & hard-to-target cell types involved in chronic diseases …
March 12, 2025

Read more

AbbVie & Gubra
News

AbbVie Enters into a Global License Agreement with Gubra to Develop & Commercialize GUB014295 to Treat Obesity

Shots: AbbVie and Gubra entered into a global license agreement to develop & commercialize GUB014295, a potential long-acting amylin analog for obesity treatment As per the deal, AbbVie will lead GUB014295's global development & commercialization, whereas Gubra will get $350M upfront, up to $1.875B development, commercial, sales milestones, with tiered royalties; transaction closure is…
March 4, 2025

Read more

News

Bio-Thera Solutions and SteinCares Add Another Biosimilar, Expanding their Alliance

Shots:  Bio-Thera Solutions has expanded its collaboration with SteinCares, granting it exclusive rights to market a third biosimilar in Brazil and the LATAM region  Bio-Thera will handle development, the US FDA & the EMA submissions to support LATAM regulatory filings & commercial supply of each biosimilar from its Chinese manufacturing facilities  SteinCares will utilize its…
December 16, 2024

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]